Cemiplimab plus chemotherapy shows five-year survival benefit in advanced NSCLC Empower-lung 3 trial
Regeneron UK Limited has reported five-year follow-up results from the [...]
Regeneron UK Limited has reported five-year follow-up results from the [...]